Transaction DateRecipientSharesTypePriceValue
18th March 2020Gail S Page8,810Payment by withholding$2.36$20,791.60
17th January 2020Gail S Page30,864Grant/award etc.$0.00
11th November 2019John Gary Potthoff10,000Open or private purchase$4.44$44,400.00
18th June 2019John J Iii Sperzel375,000Grant/award etc.$0.00
24th May 2019Javan Esfandiari9,744Open or private sale$6.95$67,726.65
23rd May 2019Javan Esfandiari12,956Open or private sale$7.15$92,582.28
22nd May 2019Javan Esfandiari7,300Open or private sale$7.41$54,125.12
6th May 2019Katherine Lyon Davis46,875Exercise of derivative$3.48$163,125.00
6th May 2019Katherine Lyon Davis22,800Payment by withholding$7.15$163,122.60
Chembio Diagnostics
Chembio Diagnostics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The company was founded in 1985 and is headquartered in Medford, NY.


Ticker: CEMI
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1092662
Employees: 324
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $36 M (99%)
Inventory, Net: $14 M (0%)
Assets, Current: $54 M (67%)
Property, Plant and Equipment, Net: $8 M (0%)
Assets: $78 M (39%)
Liabilities, Current: $14 M (121%)
Liabilities: $39 M (23%)
Common Stock, Value, Issued: $202 Th (13%)
Common Stock, Shares, Issued: $20 M (13%)
Retained Earnings (Accumulated Deficit): $84 M (17%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (10352%)
Treasury Stock, Shares: $333 Th (0%)
Stockholders' Equity (Parent): $39 M (0%)
Liabilities and Equity: $78 M (39%)
Revenue: $5 M (0%)
Research and Development: $2 M (-50%)
Operating Income/Loss: $7 M (-37%)
Provision for income taxes: $135 Th (-37%)
EPS (basic): $0.42 (-40%)
EPS (diluted): $0.42 (-40%)